Abstract: Objective To evaluate the effect of nucleos（t）ide analogues （NUCs） on renal functions in patients with hepatitis B virus（HBV）-induced decompensated liver cirrhosis. Methods In this cohort study，306 patients with HBV-associated decompensated cirrhosis were assigned to receive lamivudine（LAM，n=39），adefovir （ADV，n=73），telbivudine （LDT，n=34），entecavir （ETV，n=48），LDT and ADV （n=41） or LAM and ADV（n=25） treatment for three years，and 46 patients didn’t receive antiviral therapy for control. 97 patients were excluded because of loss，followed-up less than three years，or those in control at baseline received antiviral therapy. 209 patients were followed-up every 3 to 6 months. Changes of estimated glomerular filtration rate （eGFR），serum creatinine and urea nitrogen were analyzed. Results Among patients who received antiviral therapy，eGFR levels did not change significantly from baseline（P>0.05），but patients who received LDT or LDT and ADV combination therapy showed gradual increase in eGFR（P>0.05）；58 patients （27.8%） had mild kidney function injuries at baseline，and the normalization rates of eGFR in patients with mild renal decrease （eGFR<90 ml?min-1?1.73 m-2） at baseline were 55.6% and 50%，respectively in patients who were treated with LDT or LDT and ADV combination；The serum creatinine and urea nitrogen levels did not obviously change in all patients. Conclusion LDT monotherapy or in combination with ADV is associated with improved renal function in patients with HBV-associated decompensated cirrhosis.

Key words: Liver cirrhosis, Decompensated, Hepatitis B, Nucleos（t）ide analogues, Kidney injury